| Year |
Citation |
Score |
| 2020 |
Bastola S, Pavlyukov MS, Yamashita D, Ghosh S, Cho H, Kagaya N, Zhang Z, Minata M, Lee Y, Sadahiro H, Yamaguchi S, Komarova S, Yang E, Markert J, Nabors LB, et al. Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy. Nature Communications. 11: 4660. PMID 32938908 DOI: 10.1038/S41467-020-18189-Y |
0.365 |
|
| 2020 |
Reardon DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Ashby LS, Duic JP, Mrugala MM, Cruickshank S, Vitale L, et al. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32034072 DOI: 10.1158/1078-0432.Ccr-18-1140 |
0.391 |
|
| 2020 |
Lobbous M, Bernstock JD, Coffee E, Friedman GK, Metrock LK, Chagoya G, Elsayed G, Nakano I, Hackney JR, Korf BR, Nabors LB. An Update on Neurofibromatosis Type 1-Associated Gliomas. Cancers. 12. PMID 31906320 DOI: 10.3390/Cancers12010114 |
0.328 |
|
| 2020 |
Lamb LS, Gibbs S, Pillay T, Beelen M, Ho W, Nabors LB. Phase I trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified γδ t cells and temozolomide chemotherapy in newly diagnosed glioblastoma multiforme. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps3150 |
0.318 |
|
| 2020 |
Romo CG, Alexander BM, Agar N, Ahluwalia MS, Desai AS, Dietrich J, Kaley TJ, Peereboom DM, Takebe N, Desideri S, Fisher JD, Sims M, Ye X, Ligon KL, Nabors LB, et al. Intratumoral drug distribution of adavosertib in patients with glioblastoma: Interim results of phase I study. Journal of Clinical Oncology. 38: 2568-2568. DOI: 10.1200/Jco.2020.38.15_Suppl.2568 |
0.31 |
|
| 2020 |
Lim M, Ye X, Piotrowski AF, Desai AS, Ahluwalia MS, Walbert T, Fisher JD, Desideri S, Nabors LB, Wen PY, Grossman SA. Updated safety phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM. Journal of Clinical Oncology. 38: 2512-2512. DOI: 10.1200/Jco.2020.38.15_Suppl.2512 |
0.324 |
|
| 2020 |
Hayward EN, Yang X, Filippova N, Calano JA, Namkoong D, Kovac S, Nabors LB. Abstract 3335: Characterization and analysis of the complement immune system in glioblastoma (GBM) Immunology. 80: 3335-3335. DOI: 10.1158/1538-7445.Am2020-3335 |
0.438 |
|
| 2019 |
Fathallah-Shaykh HM, DeAtkine A, Coffee E, Khayat E, Bag AK, Han X, Warren PP, Bredel M, Fiveash J, Markert J, Bouaynaya N, Nabors LB. Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study. Plos Medicine. 16: e1002810. PMID 31136584 DOI: 10.1371/Journal.Pmed.1002810 |
0.324 |
|
| 2019 |
Kaley T, Nabors LB. Management of Central Nervous System Tumors. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 579-582. PMID 31117044 DOI: 10.6004/Jnccn.2019.5012 |
0.4 |
|
| 2019 |
Lim M, Ye X, Piotrowski AF, Desai AS, Ahluwalia MS, Walbert T, Fisher JD, Desideri S, Belcaid Z, Jackson C, Nabors LB, Wen PY, Grossman SA. Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM. Journal of Clinical Oncology. 37: 2017-2017. DOI: 10.1200/Jco.2019.37.15_Suppl.2017 |
0.306 |
|
| 2019 |
Pillai S, Gillespie GY, Nabors LB, Langford S, Langford CP, Lamb LS. Abstract 2262: Chemotherapy, checkpoint inhibition, and MGMT-modified adoptive gamma-delta (γδ) T cell-based therapy to treat post-resection, primary glioblastomas Cancer Research. 79: 2262-2262. DOI: 10.1158/1538-7445.Am2019-2262 |
0.352 |
|
| 2019 |
Lobbous M, Tucker Z, Coffee E, Nabors L. Path-35. Retrospective Analysis Of 145 Patients With Glioblastoma; Correlating Molecular Alteration Incidence With Demographics, Tumor Location, And Prognosis Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.631 |
0.351 |
|
| 2019 |
Dees K, Koo H, Hakim J, Fraser Humphreys J, Crossman D, Crowley M, Nabors L, Benveniste E, Morrow C, McFarland B. TMOD-19. ELUCIDATING THE RESISTANCE TO IMMUNOTHERAPY IN BRAIN TUMORS USING A HUMANIZED MICROBIOME MOUSE MODEL Neuro-Oncology. 21: vi266-vi266. DOI: 10.1093/Neuonc/Noz175.1118 |
0.321 |
|
| 2019 |
Barkhoudarian G, Badruddoja M, Blondin N, Chen R, Chowdhary S, Cobbs C, Dowling A, Duic P, Flores JP, Fonkem E, McClay E, Nabors L, Salacz M, Vaillant B, Kesari S. Actr-68. Feasibility Study Of The Emulate Therapeutics™ Voyager System In Patients With Recurrent Glioblastoma (Gbm) Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.109 |
0.339 |
|
| 2019 |
Yamashita D, Minata M, Yu H, Zhang S, Li C, Flanary V, Ghosh S, Lee Y, Cho H, Botta D, Guo X, Ozaki S, Yamaguchi S, Komarova S, Bastola S, ... ... Nabors L, et al. TMIC-12. TUMOR EDGE-DESTINED CELLS IN GBM CELLS IN A CELL-INTRINSIC MECHANISM Neuro-Oncology. 21: vi249-vi249. DOI: 10.1093/Neuonc/Noz175.1046 |
0.382 |
|
| 2019 |
Ahluwalia M, Dhruv H, Fallah J, Berens M, Drappatz J, Ye X, Lesser G, Cloughesy T, Walbert T, Holdhoff M, Peereboom D, Nabors L, Wen P, Grossman S, Rogers L. ACTR-43. GENOMIC ANALYSIS OF RESPONDERS OF PHASE II TRIAL OF TEMOZOLOMIDE AND TRC-102 (BASE EXCISION REPAIR INHIBITOR) IN BEVACIZUMAB-NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE Neuro-Oncology. 21: vi23-vi23. DOI: 10.1093/Neuonc/Noz175.085 |
0.372 |
|
| 2019 |
Lamb L, Markert J, Gillespie GY, Beelen M, Langford C, Pereboeva L, Youngblood S, Nabors L. ATIM-22. PHASE I TRIAL OF DRUG RESISTANT IMMUNOTHERAPY: A FIRST-IN-CLASS COMBINATION OF MGMT-MODIFIEDγδ T CELLS AND TEMOZOLOMIDE CHEMOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.021 |
0.309 |
|
| 2018 |
Filippova N, Yang X, An Z, Nabors LB, Pereboeva L. Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment. Journal of Cancer Science & Therapy. 10: 190-197. PMID 30393513 DOI: 10.4172/1948-5956.1000543 |
0.343 |
|
| 2018 |
Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, et al. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro-Oncology. PMID 29982805 DOI: 10.1093/Neuonc/Noy091 |
0.364 |
|
| 2018 |
Miller B, Peeri NC, Nabors LB, Creed JH, Thompson ZJ, Rozmeski CM, LaRocca RV, Chowdhary S, Olson JJ, Thompson RC, Egan KM. Handedness and the risk of glioma. Journal of Neuro-Oncology. PMID 29332185 DOI: 10.1007/S11060-018-2759-Y |
0.307 |
|
| 2018 |
Peereboom DM, Nabors LB, Kumthekar P, Badruddoja MA, Fink KL, Lieberman FS, Phuphanich S, Dunbar EM, Walbert T, Schiff D, Tran DD, Ashby LS, Butowski NA, Iwamoto FM, Lindsay R, et al. Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival. Journal of Clinical Oncology. 36: 2058-2058. DOI: 10.1200/Jco.2018.36.15_Suppl.2058 |
0.309 |
|
| 2017 |
Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, et al. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. Journal of the National Comprehensive Cancer Network : Jnccn. 15: 1331-1345. PMID 29118226 DOI: 10.6004/Jnccn.2017.0166 |
0.334 |
|
| 2017 |
van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, et al. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Cancer Chemotherapy and Pharmacology. PMID 29075855 DOI: 10.1007/S00280-017-3451-1 |
0.333 |
|
| 2017 |
Filippova N, Yang X, Ananthan S, Sorochinsky A, Hackney JR, Gentry Z, Bae S, King P, Nabors LB. Hu Antigen R (HuR) multimerization contributes to glioma disease progression. The Journal of Biological Chemistry. PMID 28790173 DOI: 10.1074/Jbc.M117.797878 |
0.308 |
|
| 2017 |
Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, Leal J, Fisher JD, Desideri S, Grossman SA, Wahl RL, et al. Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Neuro-Oncology. PMID 28371832 DOI: 10.1093/Neuonc/Nox020 |
0.314 |
|
| 2017 |
Alexander BM, Trippa L, Gaffey SC, Arrillaga I, Lee EQ, Tanguturi SK, Ahluwalia MS, Colman H, Galanis E, Groot JFD, Drappatz J, Lassman AB, Nabors LB, Reardon DA, Schiff D, et al. Individualized screening trial of innovative glioblastoma therapy (INSIGhT). Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps2079 |
0.365 |
|
| 2017 |
Goldlust SA, Nabors LB, Mohile N, Benkers TL, Hsu SH, Silberman S, Singer S, Rao M, Cappello L, Farmer G. Final results from the dose-escalation stage of a phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma. Journal of Clinical Oncology. 35: 2021-2021. DOI: 10.1200/Jco.2017.35.15_Suppl.2021 |
0.389 |
|
| 2017 |
Alexander BM, Ahluwalia MS, Desai AS, Dietrich J, Kaley TJ, Peereboom DM, Takebe N, Supko JG, Desideri S, Fisher JD, Sims M, Ye X, Nabors LB, Grossman SA, Wen PY. Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM. Journal of Clinical Oncology. 35: 2005-2005. DOI: 10.1200/Jco.2017.35.15_Suppl.2005 |
0.373 |
|
| 2017 |
Lassman AB, Bent MJVD, Gan HK, Reardon DA, Kumthekar P, Butowski NA, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Gomez EJ, Lee H, et al. Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial Journal of Clinical Oncology. 35: 2003-2003. DOI: 10.1200/Jco.2017.35.15_Suppl.2003 |
0.338 |
|
| 2017 |
Goldlust S, Nabors L, Mohile N, Benkers T, Hsu S, Silberman S, Singer S, Rao M, Cappello L, Farmer G. Actr-28. Final Results From The Dose-Escalation Stage Of A Phase 1/2 Trial Of Tpi 287, A Brain Penetrable Microtubule Inhibitor, Plus Bevacizumab In Patients With Recurrent Glioblastoma Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.023 |
0.367 |
|
| 2017 |
Dulaney C, Popple RA, Warren P, Nabors LB, Bredel M, Fiveash JB. Volume of Irradiated Brain is Associated With Severe Lymphopenia in Patients With Glioblastoma Multiforme International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.761 |
0.307 |
|
| 2017 |
Dover L, Dulaney C, McDonald A, Nabors LB, Warren P, Rocque G, Fiveash JB. Predictability of Life Expectancies of Malignant Brain Tumor Patients by Their Managing Physicians International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.1842 |
0.331 |
|
| 2016 |
Nabors LB. Central Nervous System: Notable Developments in the Management of Primary and Recurrent Gliomas Journal of the National Comprehensive Cancer Network. 14: 681-684. PMID 27226514 DOI: 10.6004/Jnccn.2016.0192 |
0.411 |
|
| 2016 |
Weller M, Nabors LB, Gorlia T, Leske H, Rushing E, Bady P, Hicking C, Perry J, Hong YK, Roth P, Wick W, Goodman SL, Hegi ME, Picard M, Moch H, et al. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. Oncotarget. PMID 26918452 DOI: 10.18632/Oncotarget.7588 |
0.351 |
|
| 2016 |
Egan KM, Nabors LB, Thompson ZJ, Rozmeski CM, Anic GA, Olson JJ, LaRocca RV, Chowdhary SA, Forsyth PA, Thompson RC. Analgesic use and the risk of primary adult brain tumor. European Journal of Epidemiology. PMID 26894804 DOI: 10.1007/S10654-016-0129-7 |
0.338 |
|
| 2016 |
Bent MJVD, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski NA, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Gomez EJ, Lee H, et al. Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM). Journal of Clinical Oncology. 34: 2542-2542. DOI: 10.1200/Jco.2016.34.15_Suppl.2542 |
0.376 |
|
| 2016 |
Goldlust SA, Nabors LB, Mohile N, Benkers TL, Hsu SH, Silberman S, Singer S, Farmer G. Phase 1/2 trial of bevacizumab plus TPI 287, a brain penetrable anti-microtubule agent, in patients with recurrent glioblastoma. Journal of Clinical Oncology. 34: 2055-2055. DOI: 10.1200/Jco.2016.34.15_Suppl.2055 |
0.383 |
|
| 2015 |
Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Brown P, Butowski N, Chamberlain MC, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, et al. Central Nervous System Cancers, Version 1.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 1191-202. PMID 26483059 DOI: 10.6004/Jnccn.2015.0148 |
0.33 |
|
| 2015 |
Reardon DA, Schuster JM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Desjardins A, Ashby LS, Duic JP, Mrugala MM, Werner A, Hawthorne T, He Y, et al. 107 ReACT: Overall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma. Neurosurgery. 62: 198-199. PMID 26181953 DOI: 10.1227/01.Neu.0000467069.86811.3F |
0.39 |
|
| 2015 |
Martin RC, Gerstenecker A, Nabors LB, Marson DC, Triebel KL. Impairment of medical decisional capacity in relation to Karnofsky Performance Status in adults with malignant brain tumor. Neuro-Oncology Practice. 2: 13-19. PMID 26034637 DOI: 10.1093/Nop/Npu030 |
0.328 |
|
| 2015 |
Robert SM, Buckingham SC, Campbell SL, Robel S, Holt KT, Ogunrinu-Babarinde T, Warren PP, White DM, Reid MA, Eschbacher JM, Berens ME, Lahti AC, Nabors LB, Sontheimer H. SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. Science Translational Medicine. 7: 289ra86. PMID 26019222 DOI: 10.1126/Scitranslmed.Aaa8103 |
0.364 |
|
| 2015 |
Conry RM, Sullivan JC, Nabors LB. Ipilimumab-induced encephalopathy with a reversible splenial lesion. Cancer Immunology Research. 3: 598-601. PMID 25922203 DOI: 10.1158/2326-6066.Cir-15-0035 |
0.315 |
|
| 2015 |
Bag AK, Kim H, Gao Y, Bolding M, Warren PP, Fathallah-Shaykh HM, Gurler D, Markert JM, Fiveash J, Beasley TM, Khawaja A, Friedman GK, Chapman PR, Nabors LB, Han X. Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas. Journal of Neuro-Oncology. 122: 585-93. PMID 25711673 DOI: 10.1007/S11060-015-1751-Z |
0.318 |
|
| 2015 |
Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, Mathieu D, Phuphanich S, Cseh A, Fu Y, Cong J, Wind S, Eisenstat DD. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro-Oncology. 17: 430-9. PMID 25140039 DOI: 10.1093/Neuonc/Nou160 |
0.4 |
|
| 2015 |
Holdhoff M, Ye X, Nabors LB, Desai AS, Mikkelsen T, Lesser G, Read WL, Lieberman FS, Supko J, Fisher JD, Desideri S, Grossman SA, Schiff D, Investigators A. Timed-sequential therapy with mibefradil and temozolomide in patients with recurrent high-grade gliomas: A phase I Adult Brain Tumor Consortium study. Journal of Clinical Oncology. 33: 2033-2033. DOI: 10.1200/Jco.2015.33.15_Suppl.2033 |
0.373 |
|
| 2015 |
Reardon DA, Schuster J, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Desjardins A, Ashby LS, Duic JP, Mrugala MM, Werner A, Hawthorne T, He Y, et al. ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. Journal of Clinical Oncology. 33: 2009-2009. DOI: 10.1200/Jco.2015.33.15_Suppl.2009 |
0.307 |
|
| 2015 |
Reardon DA, Desjardins A, Schuster J, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Ashby LS, Duic JP, Mrugala MM, Werner A, Vitale L, He Y, et al. IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov218.08 |
0.367 |
|
| 2014 |
Clark GM, McDonald AM, Nabors LB, Fathalla-Shaykh H, Han X, Willey CD, Markert JM, Guthrie BL, Bredel M, Fiveash JB. Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience. Neuro-Oncology Practice. 1: 172-177. PMID 26034629 DOI: 10.1093/Nop/Npu028 |
0.422 |
|
| 2014 |
Nabors LB, Portnow J, Ammirati M, Brem H, Brown P, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Hesser D, Holdhoff M, Junck L, et al. Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 1517-23. PMID 25361798 DOI: 10.6004/Jnccn.2014.0151 |
0.337 |
|
| 2014 |
Harada S, Fallon KB, Reddy A, Nabors LB. Molecular Pathology: SC18-1 INTERESTING CASE - ACTIONABLE MUTATION IN A CASE WITH A RECURRENT PLEOMORPHIC XANTHOASTROCYTOMA WITH ANAPLASTIC FEATURES. Pathology. 46: S28-9. PMID 25188122 DOI: 10.1097/01.Pat.0000454148.09652.Ea |
0.351 |
|
| 2014 |
Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, ... ... Nabors LB, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. The Lancet. Oncology. 15: 1100-8. PMID 25163906 DOI: 10.1016/S1470-2045(14)70379-1 |
0.339 |
|
| 2014 |
Bag AK, Cezayirli PC, Davenport JJ, Gaddikeri S, Fathallah-Shaykh HM, Cantor A, Han XS, Nabors LB. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. Journal of Neuro-Oncology. 120: 361-70. PMID 25098699 DOI: 10.1007/S11060-014-1560-9 |
0.307 |
|
| 2014 |
Han X, Zhang W, Yang X, Wheeler CG, Langford CP, Wu L, Filippova N, Friedman GK, Ding Q, Fathallah-Shaykh HM, Gillespie GY, Nabors LB. The role of Src family kinases in growth and migration of glioma stem cells. International Journal of Oncology. 45: 302-10. PMID 24819299 DOI: 10.3892/Ijo.2014.2432 |
0.679 |
|
| 2014 |
Han X, Li R, Zhang W, Yang X, Wheeler CG, Friedman GK, Province P, Ding Q, You Z, Fathallah-Shaykh HM, Gillespie GY, Zhao X, King PH, Nabors LB. Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. Journal of Neuro-Oncology. 118: 61-72. PMID 24664369 DOI: 10.1007/S11060-014-1419-0 |
0.711 |
|
| 2014 |
Warren P, Szaflarski J, Nabors L. Sm-10Anti-Epileptic Drugs And Cortical Irritability In Patients With Tumoral Epilepsies. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou277.9 |
0.329 |
|
| 2014 |
Reardon D, Schuster J, Tran D, Fink K, Nabors L, Li G, Lukas R, Desjardins A, Ashby L, Duic JP, Aneiro L, Hawthorne T, Green J, Yellin M, Davis T, et al. IT-30ReACT: A PHASE II STUDY OF RINDOPEPIMUT VACCINE (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou258.28 |
0.378 |
|
| 2014 |
Nabors LB, Filippova N, Yang X. Hur Dependent Regulation Of Centrosomes Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou206.74 |
0.311 |
|
| 2013 |
Hegi ME, Gorlia T, Erridge S, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Weyerbrock A, Hau P, Taphoorn MJ, Nabors LB, Reardon DA, Van Den Bent MJ, Perry JR, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O(6)-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: LBA2009. PMID 28136055 DOI: 10.1200/Jco.2013.31.18_Suppl.Lba2009 |
0.339 |
|
| 2013 |
Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, et al. Central nervous system cancers. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 1114-51. PMID 24029126 DOI: 10.6004/Jnccn.2013.0132 |
0.405 |
|
| 2013 |
Reardon DA, Groves MD, Wen PY, Nabors L, Mikkelsen T, Rosenfeld S, Raizer J, Barriuso J, McLendon RE, Suttle AB, Ma B, Curtis CM, Dar MM, de Bono J. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 900-8. PMID 23363814 DOI: 10.1158/1078-0432.Ccr-12-1707 |
0.409 |
|
| 2013 |
Gerstner ER, Levine M, Ye X, Mikkelsen T, Nabors LB, Olson JJ, Kaley TJ, Wen PY, Batchelor T, Grossman SA. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Journal of Clinical Oncology. 31: 2054-2054. DOI: 10.1200/Jco.2013.31.15_Suppl.2054 |
0.442 |
|
| 2013 |
Blakeley JO, Fisher JD, Lieberman FS, Lupo J, Nabors LB, Crane J, Wen PY, Cote A, Peereboom DM, Wen Q, Cloughesy TF, Robins HI, Desideri S, Grossman SA, Ye X, et al. Imaging biomarkers of ramucirumab and olaratumab in patients with recurrent glioblastoma. Journal of Clinical Oncology. 31: 2044-2044. DOI: 10.1200/Jco.2013.31.15_Suppl.2044 |
0.331 |
|
| 2012 |
Hackney JR, Palmer CA, Riley KO, Cure JK, Fathallah-Shaykh HM, Nabors LB. Primary central nervous system angiosarcoma: two case reports. Journal of Medical Case Reports. 6: 251. PMID 22909122 DOI: 10.1186/1752-1947-6-251 |
0.314 |
|
| 2012 |
Xiao Y, Decker PA, Rice T, McCoy LS, Smirnov I, Patoka JS, Hansen HM, Wiemels JL, Tihan T, Prados MD, Chang SM, Berger MS, Kosel ML, Fridley BL, Lachance DH, ... ... Nabors LB, et al. SSBP2 variants are associated with survival in glioblastoma patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3154-62. PMID 22472174 DOI: 10.1158/1078-0432.Ccr-11-2778 |
0.344 |
|
| 2012 |
Wheeler C, Nabors LB, Barnum S, Yang X, Hu X, Schoeb TR, Chen D, Ardelt AA, King PH. Sex hormone-dependent attenuation of EAE in a transgenic mouse with astrocytic expression of the RNA regulator HuR Journal of Neuroimmunology. 246: 34-37. PMID 22445740 DOI: 10.1016/J.Jneuroim.2012.02.014 |
0.661 |
|
| 2011 |
Eisenstat DD, Nabors LB, Mason WP, Perry JR, Shapiro WR, Kavan P, Phuphanich S, Fu Y, Cong XJ, Shahidi M, Reardon DA. A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2010. PMID 28023857 DOI: 10.1200/Jco.2011.29.15_Suppl.2010 |
0.36 |
|
| 2011 |
Nabors LB, Supko JG, Rosenfeld M, Chamberlain M, Phuphanich S, Batchelor T, Desideri S, Ye X, Wright J, Gujar S, Grossman SA. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma Neuro-Oncology. 13: 1324-1330. PMID 21954442 DOI: 10.1093/Neuonc/Nor145 |
0.381 |
|
| 2011 |
Rudek MA, New P, Mikkelsen T, Phuphanich S, Alavi JB, Nabors LB, Piantadosi S, Fisher JD, Grossman SA. Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. Journal of Neuro-Oncology. 105: 375-81. PMID 21547395 DOI: 10.1007/S11060-011-0602-9 |
0.354 |
|
| 2011 |
Filippova N, Yang X, Wang Y, Gillespie GY, Langford C, King PH, Wheeler C, Nabors LB. The RNA-binding protein HuR promotes glioma growth and treatment resistance. Molecular Cancer Research : McR. 9: 648-59. PMID 21498545 DOI: 10.1158/1541-7786.Mcr-10-0325 |
0.714 |
|
| 2011 |
Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R. Cilengitide: An RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies Future Oncology. 7: 339-354. PMID 21417900 DOI: 10.2217/Fon.11.8 |
0.395 |
|
| 2011 |
Egan KM, Thompson RC, Nabors LB, Olson JJ, Brat DJ, Larocca RV, Brem S, Moots PL, Madden MH, Browning JE, Ann Chen Y. Cancer susceptibility variants and the risk of adult glioma in a US case-control study. Journal of Neuro-Oncology. 104: 535-42. PMID 21203894 DOI: 10.1007/S11060-010-0506-0 |
0.33 |
|
| 2011 |
Niemeyer KN, Pan E, Thompson RC, Nabors LB, Olson JJ, Browning JE, Madden MH, Chen A, Yachnis AT, Egan KM. Abstract 877: Genetic variation in podoplanin in relation to glioma risk and outcome Cancer Research. 71: 877-877. DOI: 10.1158/1538-7445.Am2011-877 |
0.333 |
|
| 2010 |
Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, Fisher J. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2443-9. PMID 20371685 DOI: 10.1158/1078-0432.Ccr-09-3106 |
0.374 |
|
| 2010 |
Nabors LB, Fiveash JB, Markert JM, Kekan MS, Gillespie GY, Huang Z, Johnson MJ, Meleth S, Kuo H, Gladson CL, Fathallah-Shaykh HM. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Archives of Neurology. 67: 313-9. PMID 20212229 DOI: 10.1001/Archneurol.2010.16 |
0.393 |
|
| 2010 |
Nabors LB, Fink K, Reardon DA, Lesser GJ, Trusheim J, Raval SN, Hicking C, Picard M, Mikkelsen T. Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: Protocol of a multicenter, randomized, open-label, controlled phase II study. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps151 |
0.377 |
|
| 2010 |
Blakeley JO, Ye X, Grossman SA, Mikkelsen T, Rosenfeld MR, Bradley CR, Eichler AF, Nabors LB, Desideri S, Supko JG. Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma. Journal of Clinical Oncology. 28: 2012-2012. DOI: 10.1200/Jco.2010.28.15_Suppl.2012 |
0.341 |
|
| 2010 |
Fink K, Mikkelsen T, Nabors LB, Ravin P, Plotkin SR, Schiff D, Hicking C, Picard M, Reardon DA. Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: A randomized phase IIa study. Journal of Clinical Oncology. 28: 2010-2010. DOI: 10.1200/Jco.2010.28.15_Suppl.2010 |
0.378 |
|
| 2009 |
Akella NS, Nabors LB, Rosenfeld SS, Chamberlain MC, Mrugala MM, Jacoby DB, O'Neill AM. A phase I evaluation of intravenous TM601 in recurrent glioblastoma: Use of perfusion MRI to monitor antiangiogenic effects. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2041. PMID 27964654 DOI: 10.1200/Jco.2009.27.15_Suppl.2041 |
0.362 |
|
| 2009 |
Karrasch M, Gillespie GY, Braz E, Liechty PG, Nabors LB, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Markert JM. Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2042. PMID 27964649 DOI: 10.1200/Jco.2009.27.15_Suppl.2042 |
0.315 |
|
| 2009 |
Supko JG, Grossman SA, Peereboom DM, Chowdhary S, Lesser GJ, Nabors LB, Mikkelsen T, Desideri S, Batchelor TT. Feasibility and phase I trial of tandutinib in patients with recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2039. PMID 27964617 DOI: 10.1200/Jco.2009.27.15_Suppl.2039 |
0.348 |
|
| 2009 |
Kekan M, Fiveash J, Markert JM, Gillespie GY, Kuo H, Meleth S, Gladson CL, Nabors LB. A phase I study of ABT 510 and concurrent temozolamide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2023. PMID 27964603 DOI: 10.1200/Jco.2009.27.15_Suppl.2023 |
0.35 |
|
| 2009 |
Fiveash JB, Chowdhary SA, Peereboom D, Mikkelsen T, Nabors LB, Lesser GJ, Rosenfeld MR, Ye X, Grossman SA. NABTT-0702: A phase II study of R-(-)-gossypol (AT-101) in recurrent glioblastoma multiforme (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2010. PMID 27964593 DOI: 10.1200/Jco.2009.27.15_Suppl.2010 |
0.347 |
|
| 2009 |
Nabors LB, Mikkelsen T, Batchelor T, Lesser G, Rosenfeld M, Ye X, Piantadosi S, Olson J, Brem S, Grossman S. NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2001. PMID 27964566 DOI: 10.1200/Jco.2009.27.15_Suppl.2001 |
0.385 |
|
| 2009 |
Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, Fisher J. Current survival statistics for patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the United States. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2003. PMID 27964564 DOI: 10.1200/Jco.2009.27.15_Suppl.2003 |
0.333 |
|
| 2009 |
Gribbin TE, Senzer N, Raizer JJ, Shen S, Nabors LB, Wiranowska M, Fiveash JB. A phase I evaluation of intravenous (IV) (131)I-chlorotoxin delivery to solid peripheral and intracranial tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e14507. PMID 27963538 DOI: 10.1200/Jco.2009.27.15_Suppl.E14507 |
0.396 |
|
| 2009 |
Shen S, Nabors LB, Raizer JJ, Fiveash JB, Spies S, Costello R, O'Neill AM. Dosimetry study of a phase II multiple-dose intracavitary administration of (131)I-TM601 in adult patients with recurrent high-grade glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e13006. PMID 27962762 DOI: 10.1200/Jco.2009.27.15_Suppl.E13006 |
0.398 |
|
| 2009 |
Lu L, Wang S, Zheng L, Li X, Suswam EA, Zhang X, Wheeler CG, Nabors LB, Filippova N, King PH. Amyotrophic lateral sclerosis-linked mutant SOD1 sequesters Hu antigen R (HuR) and TIA-1-related protein (TIAR): implications for impaired post-transcriptional regulation of vascular endothelial growth factor. The Journal of Biological Chemistry. 284: 33989-98. PMID 19805546 DOI: 10.1074/Jbc.M109.067918 |
0.682 |
|
| 2009 |
Nabors LB, Palmer CA, Julian BA, Przekwas AM, Kew CE. Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 9: 1243-8. PMID 19422350 DOI: 10.1111/J.1600-6143.2009.02598.X |
0.334 |
|
| 2009 |
Kvale EA, Murthy R, Taylor R, Lee JY, Nabors LB. Distress and quality of life in primary high-grade brain tumor patients Supportive Care in Cancer. 17: 793-799. PMID 19421789 DOI: 10.1007/S00520-008-0551-9 |
0.323 |
|
| 2009 |
Pike MM, Stoops CN, Langford CP, Akella NS, Nabors LB, Gillespie GY. High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI. Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 61: 615-25. PMID 19235262 DOI: 10.1002/Mrm.21931 |
0.349 |
|
| 2009 |
Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Gillespie GY. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 199-207. PMID 18957964 DOI: 10.1038/Mt.2008.228 |
0.39 |
|
| 2007 |
Anderson JC, Grammer JR, Wang W, Nabors LB, Henkin J, Stewart JE, Gladson CL. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biology & Therapy. 6: 454-62. PMID 17384534 |
0.305 |
|
| 2007 |
Nabors LB, Rosenfeld M, Chamberlain M, Phuphanich S, Batchelor T, Supko J, Desideri S, Xiaobu Y, Wright J, Grossman S. A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401) Journal of Clinical Oncology. 25: 2058-2058. DOI: 10.1200/Jco.2007.25.18_Suppl.2058 |
0.369 |
|
| 2007 |
Fiveash JB, Sawrie SM, Guthrie BL, Spencer SA, Meredith RF, Markert JM, Nordal RA, Conry RM, Nabors LB. A phase II study of radiosurgery and temozolomide for patients with one to four brain metastases Journal of Clinical Oncology. 25: 2048-2048. DOI: 10.1200/Jco.2007.25.18_Suppl.2048 |
0.378 |
|
| 2007 |
Fiveash J, Nabors L, Raizer J, Avgeropoulos N, Modarresifar H, Shen S. Tumor Specific Targeting of Intravenous 131I-chlorotoxin (TM-601) in Patients With Recurrent Glioma International Journal of Radiation Oncology*Biology*Physics. 69: S257-S258. DOI: 10.1016/J.Ijrobp.2007.07.1266 |
0.377 |
|
| 2006 |
Mamelak AN, Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB, Fiveash JB, Shen S, Khazaeli MB, Colcher D, Liu A, Osman M, Guthrie B, Schade-Bijur S, Hablitz DM, Alvarez VL, et al. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma Journal of Clinical Oncology. 24: 3644-3650. PMID 16877732 DOI: 10.1200/Jco.2005.05.4569 |
0.308 |
|
| 2006 |
Phuphanich S, Supko J, Carson KA, Grossman SA, Nabors LB, Mikkelsen T, Lesser G, Rosenfeld M, Desideri S, Olson J. Phase I trial of bortezomib in adults with recurrent malignant glioma Journal of Clinical Oncology. 24: 1567-1567. DOI: 10.1200/Jco.2006.24.18_Suppl.1567 |
0.349 |
|
| 2006 |
Fiveash JB, Nabors LB, Mamelak AN, Avgeropoulos NG, Guthrie BL, Salomon NW, Portnow J, Bucholz RD. Safety and tolerance of multiple weekly intracavitary injections of 131I-chlorotoxin (TM-601): Preliminary results of a prospective clinical trial in patients with recurrent glioblastoma multiforme Journal of Clinical Oncology. 24: 1555-1555. DOI: 10.1200/Jco.2006.24.18_Suppl.1555 |
0.368 |
|
| 2005 |
Krishnan S, Brown P, Ballman K, Fiveash J, Uhm J, Giannini C, Geoffroy F, Nabors L, Buckner J. Phase I trial of erlotinib with radiation therapy (RT) in patients with glioblastoma multiforme (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 1513. PMID 27947117 DOI: 10.1200/Jco.2005.23.16_Suppl.1513 |
0.381 |
|
| 2005 |
Lesser GJ, Grossman SA, Carson K, Phupanich S, Batchelor T, Peereboom D, Nabors LB, Supko J, Hausheer F. Phase I study of karenitecin in the treatment of recurrent malignant gliomas (MG) Journal of Clinical Oncology. 23: 1527-1527. DOI: 10.1200/Jco.2005.23.16_Suppl.1527 |
0.326 |
|
| 2004 |
Newman AJ, Fiveash J, Rosenfeld S, Johnson M, Diasio R, Wang W, Cockrell-Donohue A, Nabors LB. A phase I study of capecitabine and concurrent radiotherapy (RT) for patients with newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1537. PMID 28015410 DOI: 10.1200/Jco.2004.22.14_Suppl.1537 |
0.418 |
|
| 2004 |
Batchelor TT, Gilbert MR, Supko JG, Carson KA, Nabors LB, Grossman SA, Lesser GJ, Mikkelsen T, Phuphanich S. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro-Oncology. 6: 21-7. PMID 14769136 DOI: 10.1215/S1152851703000218 |
0.373 |
|
| 2004 |
Meredith R, Nabors L, Shen S, Fiveash J, Besh S, LoBuglio A, Forero-Torres A. Treatment of a B-Cell, Primary Central Nervous System Lymphoma Patient with Radioimmunotherapy Using Zevalin®: A Proof-of-Principal Case. Blood. 104: 4639-4639. DOI: 10.1182/Blood.V104.11.4639.4639 |
0.37 |
|
| 2004 |
Shen S, Mamelak A, Raubitschek A, Colcher D, Liu A, Rosenfeld S, Nabors L, Fiveash J, Khazaeli M, Bucholz R, Alvarez V, Gonda M. Dosimetry of Phase I/II study of intracavitary administered I-131-TM-601 peptide in patients with recurrent high-grade glioma International Journal of Radiation Oncology*Biology*Physics. 60: S259. DOI: 10.1016/J.Ijrobp.2004.07.033 |
0.318 |
|
| Show low-probability matches. |